What is echinacoside and what plants does it come from?

Echinacoside (ECH) is a naturally occurring polyphenolic caffeic acid glycoside with the molecular formula C₃₅H₄₄O₂₀. It is found primarily in the roots of Echinacea angustifolia, in lesser amounts in Echinacea purpurea, and in Cistanche deserticola, a holoparasitic desert plant used in Traditional Chinese Medicine. Concentrations in Echinacea extracts have been measured at approximately 3.58 mg/mL by HPLC, while natural yields from C. deserticola are low enough to have prompted yeast-based biosynthetic engineering yielding 7.52 ± 1.42 mg/L.

Does echinacoside actually absorb into the bloodstream when taken orally?

Oral bioavailability of echinacoside is critically poor: a pharmacokinetic study in 9 healthy human volunteers found echinacoside completely undetectable in plasma at all timepoints following oral tablet ingestion. In rats, absolute oral bioavailability was measured at only 0.83% (Cmax = 612.2 ± 320.4 ng/mL at 100 mg/kg), and Caco-2 intestinal permeability assays showed an apparent permeability of approximately 10⁻⁷ cm/s, consistent with passive diffusion-limited absorption. This near-zero human bioavailability is a major translational barrier that limits the clinical relevance of positive preclinical findings.

Is echinacoside effective for Parkinson's disease or neuroprotection?

Echinacoside has shown neuroprotective activity in rodent models of Parkinson's disease, with pharmacokinetic data demonstrating measurable plasma exposure at 20 mg/kg oral dosing (Cmax = 403.6 ± 52.3 ng/mL) in treated animals. However, no human clinical trials have evaluated echinacoside's efficacy for Parkinson's disease or any other neurological condition, and the undetectable plasma levels observed in healthy human volunteers following oral dosing raise fundamental questions about whether sufficient CNS exposure can be achieved via conventional supplementation. Echinacoside's neuroprotective potential remains strictly preclinical at this time.

What is the recommended dose of echinacoside for humans?

No evidence-based human dose has been established for echinacoside because no clinical efficacy trials have been conducted and plasma levels were undetectable in the only human pharmacokinetic study available. Preclinical rodent doses of 20–100 mg/kg orally have been used in research, but these cannot be directly extrapolated to humans given the compound's 0.83% absolute bioavailability in rats and effectively zero bioavailability in humans. Commercial supplements containing Echinacea are typically standardized to total caffeic acid derivatives rather than isolated echinacoside, making specific ECH dosing guidance unavailable.

Is echinacoside safe, and are there any drug interactions?

Formal human safety data for isolated echinacoside are essentially absent; high-dose animal studies (100–200 mg/kg) have not reported acute toxicity, and near-zero oral bioavailability in humans implies minimal systemic exposure risk from standard supplement use. No specific drug interactions have been documented for echinacoside itself, though broad Echinacea preparations may theoretically interact with immunosuppressants or cytochrome P450-metabolized medications. Individuals allergic to plants in the Asteraceae family and pregnant or breastfeeding women should avoid echinacoside-containing supplements due to lack of safety data.

How does echinacoside compare to other neuroprotective compounds for brain health?

Echinacoside stands out for its dual mechanism of action—combining potent antioxidant activity with suppression of neuroinflammatory signaling pathways that damage neurons. Unlike single-mechanism compounds, echinacoside addresses both oxidative stress and inflammatory cascades implicated in neurodegenerative diseases. Research in Parkinson's models shows it protects dopaminergic neurons specifically, a mechanism not shared equally by all plant-derived neuroprotectants, making it particularly relevant for age-related neurological decline.

Why is echinacoside from Cistanche deserticola potentially more beneficial than from Echinacea for neuroprotection?

While both plant sources contain echinacoside, Cistanche deserticola (desert living cistanche) has been the primary focus of neuroprotection research, particularly in studies examining Parkinson's disease models and CNS bioavailability. The alkaline desert environment and Cistanche's traditional use in Chinese medicine for neurological conditions may influence the phytochemical profile and concentration of active compounds. However, both sources provide echinacoside; the choice may depend on extract standardization and research validation rather than inherent superiority of the plant source alone.

What does the pharmacokinetic data tell us about echinacoside's effectiveness in reaching the brain?

Pharmacokinetic studies in rodent Parkinson's models demonstrated a peak blood concentration (Cmax) of 403.6 ± 52.3 ng/mL following oral dosing at 20 mg/kg, indicating echinacoside does achieve systemic absorption and brain-relevant exposure levels. This measurable CNS penetration supports the plausibility of its neuroprotective effects observed in animal models and suggests oral bioavailability is sufficient for central nervous system activity. Translation of these rodent doses to human supplementation remains an area requiring clinical validation, as pharmacokinetics often differ significantly between species.

Echinacoside

Echinacoside is a phenylethanol glycoside whose biological activity derives from potent radical scavenging, nitric oxide inhibition, and modulation of inflammatory and neuroprotective signaling pathways. Despite demonstrating broad preclinical efficacy—including an IC₅₀ of 10.9 μM in lipid autoxidation assays and near-complete hemolysis inhibition at 3.0 μM—oral bioavailability in humans is effectively zero, with echinacoside undetectable in plasma following tablet administration in healthy volunteers.

Category: Compound Evidence: 1/10 Tier: Preliminary

Origin & History

Echinacoside is a polyphenolic caffeic acid glycoside naturally occurring in several plant species, most notably Echinacea angustifolia roots and Cistanche deserticola, a holoparasitic desert plant native to arid regions of northwestern China and Central Asia. In Echinacea species, echinacoside concentrations are higher in roots than in flowers, with E. angustifolia roots yielding significantly more than E. purpurea aerial parts. Cistanche deserticola grows parasitically on the roots of Haloxylon and Tamarix species in desert environments, and natural yields of echinacoside from this source are low enough to have prompted biosynthetic engineering approaches in yeast systems.

Historical & Cultural Context

Echinacea species, particularly E. purpurea and E. angustifolia, have been used for centuries by Indigenous peoples of North America—most notably Plains tribes such as the Lakota and Cheyenne—as remedies for infections, wounds, toothache, and as general immune tonics, though these traditional preparations were not distinguished by individual phytochemicals such as echinacoside. Cistanche deserticola, the other major botanical source of ECH, has been used in Traditional Chinese Medicine (TCM) for over a millennium under the name Rou Cong Rong, valued as a Yang-tonifying herb for kidney deficiency, impotence, and constipation, with its desert-harvested fleshy stems prepared as decoctions. The specific identification and isolation of echinacoside as a discrete chemical entity came with modern phytochemical analysis of the 20th century, predating an understanding that the compound contributed to the bioactivity of these traditional plant medicines. Contemporary interest in echinacoside has shifted from traditional immunostimulant applications to neuroprotective and anti-aging research contexts, largely driven by preclinical studies using isolated compound rather than whole-plant preparations.

Health Benefits

- **Neuroprotection**: Echinacoside has demonstrated protective effects against dopaminergic neuron degeneration in rodent Parkinson's disease models, attributed to its antioxidant activity and suppression of neuroinflammatory signaling; pharmacokinetic studies in Parkinson's model rats showed a Cmax of 403.6 ± 52.3 ng/mL at 20 mg/kg oral dosing, indicating CNS-relevant exposure in rodents.
- **Antioxidant Activity**: ECH scavenges free radicals with an inhibition time of 350 seconds at 1.851 μM in the Briggs-Rauscher oscillating reaction and achieves 90% inhibition of mouse erythrocyte hemolysis at 3.0 μM, placing it among potent plant-derived antioxidants in biochemical assays.
- **Anti-Inflammatory Effects**: ECH suppresses nitric oxide production and modulates pro-inflammatory mediator pathways, with its caffeic acid glycoside backbone implicated in downregulating inflammatory cascades in preclinical cell and animal models, though specific cytokine targets remain under investigation.
- **Hepatoprotection**: Preclinical studies indicate echinacoside exerts hepatoprotective and anti-hepatic fibrosis effects, likely through antioxidant reduction of oxidative hepatocellular stress and modulation of fibrogenic signaling, making it a candidate ingredient in liver-support research.
- **Antimicrobial and Antiviral Properties**: ECH displays antibiotic activity against select bacterial strains and antiviral effects in cell-based assays, consistent with the broad antimicrobial actions attributed to caffeic acid ester derivatives, though clinical validation in infectious disease contexts is absent.
- **Vasodilatory and Cardiovascular Effects**: Echinacoside exhibits vasodilative properties and nitric oxide-scavenging capacity that may modulate vascular tone; these effects have been characterized in isolated tissue preparations and animal models but have not been studied in human cardiovascular endpoints.
- **Antidiabetic and Anti-Tumor Potential**: Preliminary in vitro and animal data suggest ECH may influence glucose metabolism and exert cytostatic effects in certain tumor cell lines, positioning it as a research compound of interest in metabolic and oncology contexts pending mechanistic and translational validation.

How It Works

Echinacoside's primary molecular mechanism is direct free-radical scavenging, facilitated by its polyphenolic catechol moieties within the caffeic acid glycoside scaffold, enabling electron donation to neutralize reactive oxygen and nitrogen species with an IC₅₀ of 10.9 μM against linoleic acid autoxidation. It inhibits nitric oxide production—likely through suppression of inducible nitric oxide synthase (iNOS) expression—thereby attenuating downstream neuroinflammatory and vascular oxidative signaling. Cellular uptake occurs predominantly via passive diffusion, with an apparent permeability of approximately 10⁻⁷ cm/s measured in Caco-2 intestinal cell monolayers, which accounts for its extremely poor oral bioavailability (absolute bioavailability of 0.83% in rats). Neuroprotective effects in Parkinson's disease models are hypothesized to involve preservation of mitochondrial function and inhibition of apoptotic cascades in dopaminergic neurons, though the precise upstream receptors or transcription factors (e.g., Nrf2, NF-κB) modulated by ECH require further systematic elucidation.

Scientific Research

The evidence base for echinacoside consists almost entirely of in vitro biochemical assays and rodent pharmacokinetic and pharmacodynamic studies; no randomized controlled trials in human populations have been published examining efficacy endpoints such as neuroprotection, inflammation, or antioxidant capacity. A key pharmacokinetic study in healthy volunteers (n=9) administered oral ECH tablets derived from E. angustifolia and E. purpurea ethanolic extracts and found echinacoside undetectable in plasma at all measured timepoints, fundamentally questioning the translational relevance of all preclinical efficacy data. Rat pharmacokinetic studies established an absolute oral bioavailability of 0.83% at 100 mg/kg (Cmax = 612.2 ± 320.4 ng/mL, T½ = 74.4 min), confirming extensive first-pass or pre-absorptive degradation. Biosynthetic yield engineering in yeast (producing 7.52 ± 1.42 mg/L) and HPLC quantification studies (3.58 mg/mL in Echinacea extracts) provide robust analytical characterization but do not constitute clinical efficacy evidence, leaving ECH firmly in the preclinical research category.

Clinical Summary

Clinical investigation of echinacoside is limited to a single small pharmacokinetic study in 9 healthy volunteers, which found no detectable plasma concentrations following oral tablet administration—an outcome that critically undermines the clinical applicability of extensive preclinical efficacy data. No randomized controlled trials have assessed echinacoside's purported neuroprotective, anti-inflammatory, or antioxidant effects in human participants, and no dose-response, efficacy, or safety endpoints have been established in clinical settings. Preclinical rat models provide pharmacokinetic parameters (Cmax, T½, bioavailability) that demonstrate systemic exposure is achievable via intravenous routes or at very high oral doses in rodents, but these data cannot be directly extrapolated to human therapeutic dosing. Overall confidence in clinical benefit is very low; echinacoside remains a promising but unvalidated research compound whose translational potential is constrained by poor oral bioavailability.

Nutritional Profile

Echinacoside is a pure phytochemical compound (molecular formula C₃₅H₄₄O₂₀, molecular weight 786.7 g/mol) rather than a nutrient-dense food ingredient, and it does not contribute meaningfully to macronutrient or micronutrient intake at supplemental concentrations. Its structural identity as a phenylethanol glycoside places it in the phytochemical class alongside verbascoside (acteoside) and other caffeic acid esters, characterized by a β-3,4-dihydroxyphenylethyl alcohol aglycone linked to a disaccharide with two caffeic acid ester groups. In Echinacea extracts, ECH coexists with chicoric acid (up to 7.09 mg/mL), caftaric acid (4.48 mg/mL), caffeic acid (1.20 mg/mL), and chlorogenic acid (0.08 mg/mL), and the antioxidant activity of whole extracts likely reflects synergistic contributions from this polyphenol matrix. Bioavailability of echinacoside itself is critically limited: apparent permeability through Caco-2 monolayers is approximately 10⁻⁷ cm/s, absolute oral bioavailability in rats is 0.83%, and plasma detection in humans following oral administration is effectively zero, making systemic nutritional or pharmacological contribution negligible via the oral route.

Preparation & Dosage

- **Oral Tablets (Echinacea extract)**: Used in the sole human pharmacokinetic study; no efficacious dose established due to undetectable plasma levels—standard supplement dosing for echinacoside-containing Echinacea products typically references total extract (e.g., 300–500 mg extract standardized to caffeic acid derivatives), not isolated ECH.
- **Ethanolic Extracts**: Traditional preparation via two-step sequential ethanol extraction from E. purpurea flowers or E. angustifolia roots; freeze-drying preserves phenolic stability; yields 12.98–19.93% extractable material with total caffeic acid derivatives of 85.99–95.06 mg/g.
- **Preclinical Oral Dose (Rat Neuroprotection Model)**: 20 mg/kg body weight orally; not translatable to human dosing without bioavailability correction.
- **Preclinical Oral Dose (Pharmacokinetic Model)**: 100 mg/kg orally in rats (absolute bioavailability 0.83%); equivalent human-scale doses would require orders-of-magnitude adjustment and remain speculative.
- **Laboratory/Research Form**: Dissolved in DMSO, PEG300, or Tween 80 aqueous vehicles for in vivo animal studies; not applicable to human supplementation.
- **Standardization Note**: No internationally recognized standardization percentage for isolated echinacoside in commercial supplements exists; products are more commonly standardized to total caffeic acid glycosides or total phenolics rather than ECH specifically.
- **Timing**: No human clinical data to inform dosing timing recommendations.

Synergy & Pairings

Echinacoside is frequently present in extracts alongside chicoric acid, caftaric acid, and caffeic acid, and the combined antioxidant and anti-inflammatory activity of these caffeic acid derivatives in whole Echinacea preparations is hypothesized to exceed that of ECH alone through additive or synergistic radical-scavenging mechanisms. In Traditional Chinese Medicine, Cistanche deserticola preparations containing ECH are commonly combined with other Yang-tonifying herbs such as Rehmannia glutinosa and Morinda officinalis, though the pharmacological basis for any synergy specific to echinacoside has not been mechanistically characterized. Bioavailability enhancement strategies—such as complexation with cyclodextrins or co-administration with absorption enhancers like piperine—have been proposed in the research literature as necessary prerequisites before synergistic efficacy combinations can be meaningfully evaluated in vivo.

Safety & Interactions

Formal human safety data for isolated echinacoside are extremely limited; no controlled trials have characterized adverse effect profiles, maximum tolerated doses, or drug interactions specific to this compound in human subjects. High-dose animal studies (100–200 mg/kg orally in rats) have been conducted without reported acute toxicity, and the compound's near-zero oral bioavailability in humans suggests that systemic exposure—and therefore systemic toxicity risk—is minimal from conventional oral supplementation. No specific drug interactions have been identified for echinacoside in clinical literature; however, as a component of Echinacea preparations, theoretical interactions with immunosuppressants and cytochrome P450-metabolized drugs attributed to the broader Echinacea phytochemical complex cannot be excluded. No pregnancy, lactation, or pediatric safety data exist for isolated echinacoside, and individuals with known allergies to Asteraceae family plants should exercise caution with any Echinacea-derived product containing this compound.